The 1F5 mAb (IgG2a) was prepared from a mouse hybridoma cell subclone 1F5 (ATCC) in a CellMax ® bioreactor (Spectrum Laboratories) and purified on a Protein G Sepharose 4 Fast Flow column (GE Healthcare). Preparation of Fab' followed a previously reported procedure [1] . Briefly, antibodies were digested into F(ab') 2 with 10% (w/w) pepsin (Sigma) in citric buffer (pH 4.0).
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were determined by SEC, using an ÄKTA FPLC equipped with miniDAWN and OptilabREX detectors (GE Healthcare). Superose 6 HR10/30 column (GE Healthcare) was used, with sodium acetate buffer (pH 6.5) and 30% acetonitrile (v/v) as mobile phase. To remove the terminal (active) dithiobenzoate groups, the P-TT copolymer was reacted with 2,2'-azobis(2,4-dimethyl valeronitrile) (V-65) (Wako Chemicals). P-TT (34.5 mg, Mn=136 kDa) and V-65 (40× molar excess, 2.6 mg)
were added into an ampoule. After three vacuum-nitrogen cycles to remove oxygen, 0.35 mL MeOH/H + was added. The solution was bubbled with nitrogen for 15 min, sealed and reacted at 50 °C for 2 h. The end-modified copolymer was purified by precipitation into acetone twice and then dried under vacuum (yield 33.5 mg; 97%). The content of TT groups in the copolymer was determined by UV absorbance at 305 nm (molar absorptivity = 10,900 M -1 cm -1 ; in methanol) [4] .
Preparation of P-MORF2. The P-TT polymer precursor described above was reacted with MORF2-NH 2 to produce the multivalent P-MORF2 conjugate. Preparation of P-MORF2 followed a previously reported procedure [2] . A typical reaction was as follows: 4.2 mg P-TT (136 kDa; containing 2.5 µmol TT groups) was mixed with 4.2 mg (0.5 µmol) MORF2-NH 2 in 200 µL deionized water and 70 µL DMF. The solution mixture in an ampoule was stirred at RT for 24 h; then 5 µL 1-amino-2-propanol (Sigma-Aldrich) was added and stirred for another 5 to 10 min to aminolyze unreacted TT groups on the polymer chains. After reaction, the solution was filtered through a 0.22 µm syringe filter, and the conjugate was purified by SEC using ÄKTA FPLC with Superose 6 HR16/60 column (GE Healthcare) eluted with PBS (pH 7.2). P-MORF2 was characterized by UV absorbance at 265 nm after removal of unconjugated MORF2. To quantify the content of MORF2 and determine the valence (number of MORF2 per polymer chain), the fractionated P-MORF2 conjugate was freeze-dried and dissolved in 0.1 N HCl prior to UV-Vis spectroscopy analysis. A molar absorptivity of 252,000 (M -1 cm -1 ) was used for quantification of MORF2. The valence of the P-MORF2 conjugate was calculated based on the resulting MORF2 content and the Mn of the polymer backbone (136 kDa, determined by SEC).
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Confocal fluorescence microscopy
Human Burkitt's B-cell non-Hodgkin lymphoma Raji cell line (ATCC) was cultured in RPMI-1640 medium (Sigma) supplemented with 10% fetal bovine serum (HyClone) at 37 °C in a humidified atmosphere with 5% CO 2 (v/v). Experiments were performed using cells in exponential growth phase. Cells at a density of 10 5 per well were incubated with 0.5 mL rhodamine-labeled
Fab'-MORF1 (1 µM) in culture medium at 37 °C for 1 h; then the cells were washed twice with PBS prior to incubation with 0.5 mL of FITC-labeled P-MORF2 (1 µM, MORF2 equivalent) or FITClabeled P-scMORF2 (1 or 5 µM, MORF eqv.) for another 1 h. Conjugates P-MORF2 and PscMORF2 were prepared from the same polymer backbone and had a similar valence (~5 oligos/chain). After the incubation, cells were washed twice with PBS, and plated onto sterile 35-mm glass bottom dishes with 14-mm microwells (MatTek Corporation) for imaging. An Olympus laser scanning confocal microscope (FV 1000) was used. Please, note that all other experiments (except confocal microscopy) were performed with P-MORF2 containing 9 oligonucleotides/chain.
Radiolabeling of Fab'-MORF1
Iodine-125 labeling of the Fab'-MORF1 conjugate was performed immediately before use. Na 125 I (PerkinElmer) was reacted with Fab'-MORF1 in 10 mM PBS (pH 7.4) in a pre-coated iodination tube (Thermo Scientific). The reaction mixture was gently stirred at room temperature for 10 min, followed by purification with a Sephadex PD-10 column (GE Healthcare) and then a Images were acquired and analyzed under the Living Image ® (Perkin Elmer) software environment.
Region of interest (ROI) was selected by drawing contours to include the whole mice. Luciferase light unit was quantified in average radiance (photons/sec/cm 2 /sr). For ex vivo analysis, mice were injected with 3 mg luciferin 12 min prior to being sacrificed. Various organs and tissues (heart, liver, spleen, kidney, lung, intestine, stomach, muscle, brain, spinal cord, femur, tibia, and mesenteric and inguinal lymph nodes) were harvested for imaging. Acquisition parameters were as follows: 1 min exposure time, small binning, and 1 f/stop.
Microcomputed tomography (microCT) imaging
In vivo microCT imaging of mice was performed on week 10 after tumor implantation. Mice were anesthetized with 2% (v/v) isoflurane gas in oxygen and positioned left lateral on the scanner bed. The hind limbs of mice were scanned using a high-resolution microCT Quantum FX system (Perkin Elmer) at 90 keV and 160 mA, with a field of vision (FOV) of 24 mm. The acquisition time was 4.5 min. Three-dimensional (3D) reconstruction of bone architecture was performed under a Quantum FX viewer 1.3.0 software environment (Perkin Elmer).
Pathological and histopathological examination
Immediately after mice were sacrificed, the following organs and tissues were harvested for pathological evaluation: brain, heart, lung, liver, spleen, kidney, spinal cord, and lymph nodes.
These organs/tissues were fixed in 10% formalin overnight at room temperature, and then transferred and preserved in 70% ethanol. Histopathological examination was performed by a S7 blinded veterinary pathologist at Animal Reference Pathology (Salt Lake City, UT). Tissue sections (2-6 per organ) were cut at 4-µm thickness, mounted on glass slides, and stained by hematoxylin and eosin (H&E).
Patient samples analysis and apoptosis assay
Primary mantle cell lymphoma (MCL) cells were isolated from 4 patients. Two isolates were from lymph node biopsies (patients 1 and 2) and two were from the peripheral blood ( 
Supporting Discussion
Comparison with other CD20 crosslinking platforms
Several other platforms for CD20 crosslinking and apoptosis induction of B-cells have been developed [7] [8] [9] [10] [11] [12] [13] [14] [15] . One strategy is to use multivalent polymer-mAb or polymer-Fab' conjugates. For instance, multimeric rituximab bound to activated dextran [7] or lipid nanoparticles [8] have been produced. Our laboratory synthesized multivalent HPMA copolymer -anti-CD20 Fab' conjugates,
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which successfully induced apoptosis of malignant B-cells in vitro [9] [10] [11] . The advantage of such approaches [7] [8] [9] [10] [11] [12] [13] is the more straightforward one-step treatment, likely resulting to better patient compliance. However, due to the large size of the antibodies or their fragments, it is difficult to synthesize such constructs with high valency (due to steric hindrance). This undesirable feature may severely limit the therapeutic efficiency. Previously we attempted to increase the valency by synthesizing branched HPMA copolymer backbones [9] . A small amount of tetraethyleneglycol dimethacrylate was used as the crosslinker, and copolymers with high polydispersity were produced. Consequently, fractionation was required to prepare narrowly dispersed copolymers.
Other researchers used biological polymers such as DNA [12] or polypeptides [13] as scaffolds to attach antibodies or the smaller size single-chain variable fragments (scFv). These polyvalent constructs indeed achieved better efficacies than their monovalent counterparts. However, one fundamental difference between these single-treatment designs and our "binary system" reported here is that the binary systems have the advantage of performing pretargeting. Previously our laboratory has designed and developed a pilot "binary" anti-CD20 drug-free macromolecular therapeutic system using a pair of pentaheptad peptides (CCE and CCK) that formed antiparallel coiled-coil heterodimers as the biorecognition moieties [14, 15] . When compared to this previous design using peptides, the MORF oligos clearly demonstrated faster binding kinetics as well as more efficient self-assembly (equimolar MORF1/MORF2 reached binding saturation in vitro), therefore resulting in superior apoptosis induction and in vivo anti-lymphoma efficacy [2] . This is because the individual peptide sequences do not have a pronounced secondary structure at the physiological pH [16] . Fab'-CCE and P-CCK interact first via hydrophobic and electrostatic interactions, and then the oligopeptides fold into a strong antiparallel coiled-coil heterodimer.
Therefore, we aimed to identify a biorecognition pair that would bind efficiently at the 1:1 molar ratio. Morpholino oligonucleotides were selected due to their fast hybridization, excellent binding affinity and stability in plasma, as well as water-solubility [17] . 
